These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31146509)

  • 21. Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.
    Nakase H; Keum B; Ye BD; Park SJ; Koo HS; Eun CS
    Intest Res; 2016 Jul; 14(3):231-9. PubMed ID: 27433145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
    D'Haens G; Daperno M
    Curr Gastroenterol Rep; 2006 Dec; 8(6):506-12. PubMed ID: 17105690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
    Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.
    Bourreille A; Ignjatovic A; Aabakken L; Loftus EV; Eliakim R; Pennazio M; Bouhnik Y; Seidman E; Keuchel M; Albert JG; Ardizzone S; Bar-Meir S; Bisschops R; Despott EJ; Fortun PF; Heuschkel R; Kammermeier J; Leighton JA; Mantzaris GJ; Moussata D; Lo S; Paulsen V; Panés J; Radford-Smith G; Reinisch W; Rondonotti E; Sanders DS; Swoger JM; Yamamoto H; Travis S; Colombel JF; Van Gossum A;
    Endoscopy; 2009 Jul; 41(7):618-37. PubMed ID: 19588292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
    Nguyen GC; Harris ML; Dassopoulos T
    Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
    Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
    BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial occurrence and inheritance studies in inflammatory bowel disease.
    Binder V; Orholm M
    Neth J Med; 1996 Feb; 48(2):53-6. PubMed ID: 8819799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study.
    Choi YI; Kim YJ; Chung JW; Kim KO; Kim H; Park RW; Park DK
    JMIR Med Inform; 2020 Apr; 8(4):e15124. PubMed ID: 32293578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul.
    Kim ES; Chen M; Lee J; Lee CK; Kim YS
    Intest Res; 2016 Jul; 14(3):224-30. PubMed ID: 27433144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
    Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
    BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).
    Imbrizi M; Baima JP; Azevedo MFC; Andrade AR; Queiroz NSF; Chebli JMF; Chebli LA; Argollo MC; Sassaki LY; Parra RS; Quaresma AB; Vieira A; Damião AOMC; Moraes ACDS; Flores C; Zaltman C; Vilela EG; Morsoletto EM; Gonçalves Filho FA; Penna FGCE; Santana GO; Zabot GP; Parente JML; Costa MHM; Zerôncio MA; Machado MB; Cassol OS; Kotze PG; Fróes RSB; Miszputen SJ; Ambrogini Junior O; Saad-Hossne R; Coy CSR
    Arq Gastroenterol; 2023; 59(suppl 1):20-50. PubMed ID: 36995888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.
    Sood A; Ahuja V; Midha V; Sinha SK; Pai CG; Kedia S; Mehta V; Bopanna S; Abraham P; Banerjee R; Bhatia S; Chakravartty K; Dadhich S; Desai D; Dwivedi M; Goswami B; Kaur K; Khosla R; Kumar A; Mahajan R; Misra SP; Peddi K; Singh SP; Singh A
    Intest Res; 2020 Oct; 18(4):355-378. PubMed ID: 32646198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.
    Kirsner JB
    Dis Mon; 1991 Nov; 37(11):669-746. PubMed ID: 1935537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.
    Wickbom A; Bohr J; Nyhlin N; Eriksson A; Lapidus A; Münch A; Ung KA; Vigren L; Öst Å; Tysk C;
    Scand J Gastroenterol; 2018 Apr; 53(4):410-416. PubMed ID: 29546806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
    Scott FI; Lichtenstein GR
    Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory bowel disease. Part I: Nature and pathogenesis.
    Kirsner JB
    Dis Mon; 1991 Oct; 37(10):605-66. PubMed ID: 1893828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.